Metastatic Prostate Cancer Clinical Trial
— mENCOREOfficial title:
mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer: a Feasibility Trial of a Patient Decision Support Intervention
Verified date | May 2021 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients surviving with advanced prostate cancer frequently encounter time points in their disease course that require choosing among multiple options regarding systemic therapy. Interventions to improve shared decision-making through patient support measures such as question listing, and audio recording and summarizing of consultations have been shown to improve patient-reported measures of decision making quality, e.g. decreased decisional conflict and regret. However, the feasibility of consultation recording and summarizing with mobile health (mHealth) technology on patient-owned smartphones is unknown. The investigators will conduct a single-arm trial to determine feasibility and acceptability of a clinician-prompted, patient administered smartphone audio recording application and a service to summarize the recordings (Patient Support Corps or PSC), in improving decision-making quality among patients with chemotherapy-naive, progressive, metastatic castration-resistant prostate cancer (mCRPC). This trial will inform the design and conduct of a larger trial evaluating broader scale implementation of this intervention.
Status | Completed |
Enrollment | 27 |
Est. completion date | February 28, 2021 |
Est. primary completion date | February 28, 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Prostate cancer of any histology. 2. Metastatic castrate-resistant Prostate Cancer (mCRPC) 3. Progression per any Prostate Cancer Working Group 3(PCWG3) criterion. 4. Has never received chemotherapy 5. Currently receiving or has previously received any androgen-signaling inhibitors (ASI) (abiraterone, enzalutamide, apalutamide, or darolutamide) that was discontinued due to progression 6. 18 years of age or older. 7. Able to read, speak, and write in English. 8. Has an upcoming genitourinary (GU) medical oncology appointment (in-person or Zoom video visit) at University of California, San Francisco (UCSF) within 7-60 days of enrollment. 9. Has access to and ability to use an iPhone (iOS) or Android smartphone. 10. Patient's UCSF oncology provider agrees to be recorded. Exclusion Criteria: 1. Lack of decision-making capacity to provide consent to this trial. 2. Uncorrectable hearing or visual impairment hindering the ability to perform necessary tasks in the trial. 3. Any neurocognitive or psychiatric disorder hindering the ability to perform necessary tasks in the trial. |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of enrolled participants who utilized the application | Proportion of enrolled participants who create a complete audio consultation recording of the appointment using the application, measured by application metrics, at 1 week post-consultation along with 95% confidence interval will be reported. | Up to 2 weeks after the appointment | |
Secondary | Proportion of enrolled participants who listened to audio recording within 1 week after the visit | Proportion of enrolled participants who listen to the recording, measured by participant-reported survey at 1 week post-consultation along with 95% confidence interval will be reported. | Up to 2 weeks after the appointment | |
Secondary | Proportion of enrolled participants who obtain written summary of the consultation | Proportion of enrolled participants who request and receive a written summary of the consultation from the Patient Support Corps (PSC) within 1 week after the visit along with 95% confidence interval will be reported. | Up to 2 weeks after the appointment | |
Secondary | Mean participant-reported CollaboRATE scores | The CollaboRATE is a 3-item questionnaire developed to measure shared decision making in reference to the most recent appointment the participant may have had with the oncologist.
The questions are as follows: (i) How much effort was made to help you understand your health issues? (ii) How much effort was made to listen to what matters most to you about your health is-sues? (iii) How much effort was made to include what matters most to you in choosing what to do next? Each response ranges from a score of 0-9, with a response of 0 = "No effort was made" and 9="Every effort was made". Higher total scores represent more shared decision making. |
Up to 2 weeks after the appointment | |
Secondary | Mean score of participant reported Decision Regret Scale (DRS) | The DRS is a 5-item questionnaire where participants are asked to reflect on a past decision, and then asked to indicated the extent to which they agree or disagree with the statement in the regret scale by indication a number from 1 (Strongly) to 5 (Strongly Disagree) that best indicated their level of agreement. Scores are converted to a 0-100 scale with a lower scores indicating less regret. | Up to 2 weeks after the appointment | |
Secondary | Mean change in scores on the Informed subscale of the Decisional Conflict Scale (DCS) from baseline | The "Informed" subscale of the DCS consists of 3 items which measure the degree that the participant feel informed, with scores that range from 0 (strongly agree) to 4 (Strongly disagree). Scores are summed and then converted to a scale of 0-100, with lower indicating a greater degree of feeling informed. For analyzing changes in DCS information subscale, a two-tailed paired sample t-test will be used to determine whether the mean difference between pre- and post-consultation survey scores is 0 or not. | Baseline and up to 2 weeks after the appointment | |
Secondary | Mean perceived change in work burden provider-reported workload and other outcomes | The change in work burden will be determined using a provider-reported workload survey to determine whether audio recording produced a change in work burden at 1 week post-consultation among providers with enrolled participants. There are 5 possible responses: "Decreased work", "No Change", "A little more work", "Some more work", and "A lot more work". | Up to 2 weeks after the appointment | |
Secondary | Mean perceived change in provider-patient relationship quality | The change in provider-patient relationship quality will be determined using a provider-reported survey to determine whether audio recording produced a change in the provider patient relationship at 1 week post-consultation among providers with enrolled participants. There are 5 possible responses: "Negatively", "Somewhat Negatively", "No change", "Somewhat Positively", and "Positively". | Up to 2 weeks after the appointment | |
Secondary | Mean change in number of participant-initiated telephone call or portal message encounters over time | Changes in the frequency of follow-up communication between participant and clinic staff in the electronic health record from baseline (2 weeks pre-consultation to consultation) to post-consultation (consultation to 2 weeks post-consultation). | Baseline and up to 2 weeks after the appointment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Recruiting |
NCT04533958 -
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy
|
N/A | |
Not yet recruiting |
NCT06009549 -
A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
|
||
Withdrawn |
NCT05771896 -
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
|
Phase 3 | |
Completed |
NCT01981122 -
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT01233557 -
Biomarkers of Bone Resorption in Metastatic Prostate Cancer
|
N/A | |
Completed |
NCT01012141 -
Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04067713 -
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
|
||
Active, not recruiting |
NCT04332744 -
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
|
Phase 2 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04031378 -
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT02278055 -
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT04193657 -
Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
|
||
Completed |
NCT02260817 -
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
|
Phase 3 | |
Terminated |
NCT00216060 -
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
|
Phase 3 | |
Recruiting |
NCT04070209 -
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
|
Phase 2 | |
Recruiting |
NCT04925648 -
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
|
Phase 2 | |
Completed |
NCT01303705 -
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
|
Phase 1 | |
Completed |
NCT01560923 -
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
|
Phase 2 |